Crisis, what crisis? Biocorp happy with IPO which it says will help win Big Pharma customers

By Gareth Macdonald

- Last updated on GMT

Biocorp plans international business expansion after IPO
Biocorp plans international business expansion after IPO

Related tags Initial public offering

Biocorp has raised €8.9m ($9.8m) through an IPO during what it called a period of “deep macroeconomic uncertainty” and has underlined plans to grow its drug delivery tech business internationally.

The French delivery technology firm said the initial public offering (IPO) on Paris’ Alternext exchange had attracted both institutional and private backers. Investors paid €9.25 euros per share for a total of 957,867 shares.

A spokeswoman told us the “economic uncertainty” comment referred to the Greek crisis's​ impact on the European markets, explaining that: “Definitely, the crisis impacted the market and more money would have been raised without the crisis but Biocorp wanted to raise €8m​”

She contrasted this with poorer results of "other companies on the IPO ramp at the same time" ​which she said indicated that "the BioCorp story is solid​.”

Big Pharma

When Biocorp CEO Jacques Gardette announced the firm's intention to list last month​ he said going public would help attract Big Pharma drug delivery technology customers, citing the DataPen platform for diabetes drugs as a likely beneficiary. 

One to two years ahead of its competitors, DataPen has all the necessary qualities to convince pharmaceutical laboratories to sign partnership agreements and then impose itself as a reference in the treatment of chronic diseases​” Gardette said in June.

A company spokeswoman reiterated this in the context of the IPO, telling us “Biocorp’s development model is based on in-house innovations, which are later subject to commercial agreements of pharmaceutical laboratories or from their suppliers​” adding that the firm “intends to keep intellectual property and manufacturing​.”

Biocorp already counts Sanofi Pasteur – the vaccines development unit of French drug firm Sanofi – as a customer and has also recently signed contracts with Nuova Ompi, a subsidiary of the Italian group Stevanato and the Japanese company Nipro.

The firm's shares will begin trading on the Alternext exchange on Friday.

Related news

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us